Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2008.159 | A Phase IIb, Multi-center, Open-label, Follow-up Study to Assess the Safety and Efficacy of Epratuzumab in Serologically-Positive Systemic Lupus Erythematosus Patients with Active Disease Who Participated in Study SL0007 | Asso. Prof. TAM Lai Shan |
| 2007.486 | A Double-blind, Randomized, Placebo-control Trial to Assess the Effects of Hydroxychloroquine on Progression of Carotid Artery Intimal-Medial Thickening in Psoriatic Arthritis | Ms Tam Lai Shan |
| 2008.160 | SERAPHIN: Study with Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome | Prof Tam Lai Shan |
| 2008.161 | SERAPHIN-OL: Study with An ERA in Pulmonary Arterial Hypertension to Improve Clinical Outcome (Open Label) – Long-term Single-arm Open-label Extension Study of the SERAPHIN study, to Assess the Safety and Tolerability of ACT-064922 in Patients with Symptomatic Pulmonary Arterial Hypertension | Prof. TAM Lai Shan |
| 2013.470 | A multi-center, uncontrolled extension study evaluating efficacy and safety of SAR153191 on top of DMARDs in patients with active Rheumatoid Arthritis (RA) | Prof Tam Lai Shan |
| 2010.056 | Effect of anti-TNF | Prof. TAM LAI SHAN |
| 2014.082 | A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects with Lupus Nephritis | Prof. TAM Lai Shan |
| 2012.007 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis | Prof. TAM Lai Shan |
| 2009.409 | Traditional Chinese Medicine for Osteoarthritis of the Knee (TCM-OAK): A dose escalation study | Prof. Tam Lai Shan |
| 2010.491 | Effect of early intensive treatment in patients with recent-onset rheumatoid arthritis | Prof. TAM Lai Shan |
| 2013.568 | A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with ankylosing spondylitis. | Prof. TAM Lai Shan |
| 2009.429 | A Phase 2A, Randomized, Double-Blind, Active and Placebo-Controlled Study of PF-04171327 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis | Dr. TAM Lai Shan |
| 2014.167 | Exploiting the immunomodulatory and anti-inflammatory role of IL35 to modulate inflammation and autoreactive B cell activation in rheumatoid arthritis | Prof. TAM Lai Shan |
| 2008.344 | Premature Atherosclerosis in Early Rheumatoid Arthritis | Prof Tam Lai Shan |
| 2008.343 | The Chinese University of Hong Kong Early Arthritis Study | Prof Tam Lai Shan |
| 2011.541 | A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients with Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Therapy | Prof. Tam Lai Shan |
| 2008.391 | A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), A Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057 | Prof. TAM Lai Shan |
| 2012.200 | A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects with Systemic Lupus Erythematosus | Prof. TAM Lai Shan |
| 2011.378 | A Phase 3, Multicenter, Open-Label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects (EMBODY 4) | Prof. TAM Lai Shan |
| 2012.476 | Alteration in bone density and microstructure in early rheumatoid arthritis and its relationship with bone erosion: A one-year study by HR-pQCT and MRI | Prof. TAM Lai Shan |
| 2012.559 | A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are inadequate responders to or intolerant of TNF-α antagonists | Prof. TAM Lai Shan |
| 2012.558 | An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with mild to moderate systemic lupus erythematosus | Professor Tam Lai Shan |
| 2011.542 | A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia | Prof. Tam Lai Shan |
| 2012.557 | A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab | Prof. TAM Lai Shan |
| 2011.483 | Effect of treat-to-target strategies aiming at remission compared with minimal disease activity on arterial stiffness in early rheumatoid arthritis - a randomized controlled study | Prof. TAM Lai Shan |
| 2011.510 | Comparison of the effect of denosumab and alendronate on bone density and microarchitecture in rheumatoid arthritis females with low bone mass: A randomized controlled trial | Prof. Tam Lai Shan |
| 2017.261 | The impact of nurse-led programme with and without statin treatment base on traditional cardiovascular risk score or carotid ultrasound on addressing cardiovascular risk in patients with arthritis: a prospective, multicentre, randomised, controlled trial | Prof. TAM Lai Shan |
| 2016.533 | A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate |
Prof. TAM Lai Shan 譚麗珊 |
| 2015.664 | A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs |
Prof. TAM Lai Shan 譚麗珊 |
| 2014.052 | Advanced 3-D Bioimaging Technology to improve vertebral fracture prediction in patients with glucocorticoid-induced osteoporosis | Prof. TAM Lai Shan |
| 2016.551 | A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison with Mycophenolate Mofetil and Corticosteroids in Subjects with Class III/IV±V Lupus Nephritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.146 | Circulating microRNAs as biomarkers for predicting the early development, repair and progression of bone erosions in early rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2014.618 | Advanced 3-D Bioimaging Technology to assess efficacy of tight- control treatment strategies aiming at SDAI vs DAS remission in the prevention of bone loss in patients with early rheumatoid arthritis | Prof. Tam Lai Shan |
| 2015.697 | Freely circulating microRNAs as biomarkers for fracture and bone loss in female patients with systemic lupus erythematosus on long-term glucocorticoid therapy |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.037 | Identification and validation of microRNAs associated with inflammation detected by magnetic resonance imaging in patients with early rheumatoid arthritis. |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.451 | Prevention of metacarpophalangeal joints structure damage in patients with psoriatic arthritis using secukinumab |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.450 | Cost Effectiveness Analysis of Biologic Therapies for the Treatment of Rheumatoid Arthritis in Hong Kong |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2014.343 | Adaptation and validation of the Ankylosing Spondylitis Quality of Life (ASQOL) and Psoriatic Arthritis Quality of Life (PsAQOL) questionnaires in Hong Kong | Prof. TAM Lai Shan |
| 2017.446 | A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2015.334 | Characterization of the potential role of interleukin-36 (IL-36) in regulating protective and pathogenic B cells in systemic lupus erythematosus |
Dr. TAM Lai Shan 譚麗珊 |
| 2016.431 | Effect of RANKL inhibition on healing of bone erosion in rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2013.469 | The Clinical Rheumatology Systematic Treat-to-target in Asia Leadership (CRYSTAL) Project | Prof. TAM Lai Shan |
| 2016.390 | Assessment of structure changes after 4 years on the second and third metacarpophalangeal joint and distal radius in patients with psoriatic arthritis – a follow-up study using High-resolution peripheral quantitative CT (HR-pQCT) |
Prof. TAM Lai Shan 譚麗珊 |
| 2014.387 | Coronary atherosclerosis in psoriatic arthritis | Prof. TAM Lai Shan |
| 2016.366 | MicroRNAs as biomarkers for predicting the effect of anti-TNF and anti-IL6 in changes of bone erosions in rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2015.214 | Prevalence and risk factors for osteoporosis in patients with ankylosing spondylitis in Hong Kong: a cross-sectional cohort study |
Dr. TAM Lai Shan 譚麗珊 |
| 2016.359 | A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year of treatment, in patients with active lupus nephritis |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2015.065 | Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | Prof. TAM Lai Shan |
| 2013.451 | Immunopathological roles of the novel inflammatory cytokine interleukin-36 in the patients with systemic lupus erythematous | Professor TAM Lai Shan |
| 2013.300 | Immunopathological roles of the novel anti-inflammatory cytokine interleukin-35 in the patients with systemic lupus erythematous | Prof. TAM Lai Shan |
Page 217 of 289.

